Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
We measured anti-spike (S), nucleoprotein (N), and neutralizing antibodies in sera from 308 healthcare workers with a positive reverse-transcription quantitative polymerase chain reaction result for severe acute respiratory syndrome coronavirus 2 and with mild disease, collected at 2 timepoints up to 6 months after symptom onset. At month 1, anti-S and -N antibody levels were higher in male participants aged >50 years and participants with a body mass index (BMI) >25 kg/m2. At months 3–6, anti-S and anti-N antibodies were detected in 99% and 59% of individuals, respectively. Anti-S antibodies and neutralizing antibodies declined faster in men than in women, independent of age and BMI, suggesting an association of sex with evolution of the humoral response.
Article activity feed
-
-
SciScore for 10.1101/2020.11.12.20230466: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: At enrolment (From April 15 to 29 2020) written informed consent was collected and participants completed a questionnaire which covered sociodemographic characteristics, virological findings (SARS-CoV-2 RT-PCR results including date of testing) and clinical data (date of symptom onset, type of symptoms, hospitalization). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Statistical analysis: Baseline characteristics between men and women were compared using a chi-square test for categorical variable and student’s t-test for continuous variables. Cell Line Authentication Contamination: Cells were tested … SciScore for 10.1101/2020.11.12.20230466: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: At enrolment (From April 15 to 29 2020) written informed consent was collected and participants completed a questionnaire which covered sociodemographic characteristics, virological findings (SARS-CoV-2 RT-PCR results including date of testing) and clinical data (date of symptom onset, type of symptoms, hospitalization). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Statistical analysis: Baseline characteristics between men and women were compared using a chi-square test for categorical variable and student’s t-test for continuous variables. Cell Line Authentication Contamination: Cells were tested for absence of mycoplasma contamination using Mycoalert™ Mycoplasma Detection Kit (Lonza) Table 2: Resources
Antibodies Sentences Resources Study design: The objective of this longitudinal study was to assess the onset and the persistence of anti-SARS-CoV-2 antibodies in sera from mild COVID-19 healthcare workers from Strasbourg University Hospital. anti-SARS-CoV-2suggested: NoneA titration with a human anti-S monoclonal antibody (mAb 48) was added to each plate to verify the reproducibility of the assay. anti-Ssuggested: NoneSubjects were divided into “sustainer” or “decayer” categories, for anti-S IgG, anti-N IgG and neutralizing antibody responses. anti-S IgGsuggested: Noneanti-N IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Cells: 293T cells (ATCC® CRL-3216™) were grown in complete DMEM medium (10% Fetal Calf Serum, 1% Penicillin/ streptomycin). 293Tsuggested: NoneSoftware and Algorithms Sentences Resources (R Studio, PBC) or Prism 8 (Graphpad Software). Graphpadsuggested: (GraphPad, RRID:SCR_000306)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04441684 Recruiting Seroprevalence of SARS-CoV-2 in Strasbourg University Hospit… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-
